|1.||Jia, Wen Qin: 2 articles (01/2014 - 01/2010)|
|2.||Zhang, Peng: 2 articles (01/2014 - 01/2010)|
|3.||Li, Lun: 2 articles (01/2014 - 01/2010)|
|4.||Olson, William C: 2 articles (10/2010 - 02/2003)|
|5.||Tian, Jin Hui: 1 article (01/2014)|
|6.||Yang, KeHu: 1 article (01/2014)|
|7.||Jacobson, Jeffrey M: 1 article (10/2010)|
|8.||Maddon, Paul J: 1 article (10/2010)|
|9.||Saag, Michael S: 1 article (10/2010)|
|10.||Rotshteyn, Yakov: 1 article (10/2010)|
|1.||HIV Infections (HIV Infection)
01/01/2014 - "We aimed to assess the efficacy, safety, clinical disease progression and immunologic (CD4 count/percentage) and virologic (plasma HIV RNA viral load) markers of PRO 140 for HIV-infected patients in randomized controlled trials (RCTs) and quasi-randomized controlled trials (quasi-RCTs). "
|3.||Body Weight (Weight, Body)
10/01/2010 - "Prior studies have examined single intravenous doses ranging up to 5 mg/kg of body weight or up to three subcutaneous doses ranging up to 324 mg. Here we report the results of a randomized, double-blind, placebo-controlled trial that examined the antiviral activity, tolerability, and pharmacokinetics of single 5-mg/kg and 10-mg/kg intravenous infusions of PRO 140 in 31 treated subjects. "
02/01/2003 - "Inhibitors of human immunodeficiency virus type 1 attachment (CD4-immunoglobulin G subclass 2), CCR5 usage (PRO 140), and fusion (T-20) were tested on diverse primary cell types that represent the major targets both for infection in vivo and for the inhibition of trans infection of target cells by virus bound to dendritic cells. "
01/01/2001 - "Despite their divergent mechanisms of action and binding epitopes on CCR5, low nanomolar concentrations of both PRO 140 and RANTES inhibited infection of primary peripheral blood mononuclear cells (PBMC) by all CCR5-using (R5) viruses tested. "
|5.||Lymphatic Diseases (Lymphadenopathy)
|3.||Immunoglobulin G (IgG)